OEL Fastrac wins the prestigious CPhI Award for Excellence in Pharma: Regulatory Procedures and Compliance


OEL Fastrac CPhI 2020 Award

OEL Fastrac is an innovative way OEL/ADE/PDE monographs are provided, resulting in significant cost savings and greatly reduced lead-time for pharmaceutical manufacturing and contract manufacturing companies.

Affygility Solutions, a leading occupational health and safety consulting firm for the life sciences industry, announced today that its OEL Fastrac™️ platform has won the prestigious CPhI Excellence in Pharma Award for the Regulatory Procedures and Compliance category.

OEL Fastrac™ is an innovative online service by Affygility Solutions that provides life science professionals with high-quality documents containing the necessary information to properly classify potent compounds and protect their employees and patients from the hazards of potent active pharmaceutical ingredients. In addition, OEL Fastrac monographs contain the acceptable daily exposure limit (ADE), also known as permitted daily exposure (PDE), required under ISPE’s Risk-MaPP, EMA, and PIC/s guidance. OEL Fastrac is an innovative way OEL/ADE/PDE monographs are provided, resulting in significant cost savings and greatly reduced lead-time for pharmaceutical manufacturing and contract manufacturing companies.

The CPhI Pharma Awards celebrate the thinkers and creators driving the industry forward through their innovations, technologies and strategies.

“We are extremely excited to have Affygility Solutions receive this award,” said Dean Calhoun, CIH, President and Chief Executive Officer of Affygility Solutions. “Receipt of this award clearly demonstrates what a small team of dedicated, creative, and talented people can accomplish.”

About Affygility Solutions

Since 2002, Affygility Solutions has provided occupational health, safety, and toxicology services to the life science industry. Our services include the Affytrac EH&S management tool, potent compound safety and categorization, occupational exposure limits and acceptable daily exposure limits for active pharmaceutical ingredients, genotoxic impurity evaluations and more. We’ve provided these services to small, mid-size and large life science companies in over 65 different countries

Share article on social media or email:

Leave a Reply